Coverage
Filings
| Filing | Date |
|---|---|
| GLISTEN Trial of Linerixibat Meets Endpoint | 19 Nov 2024 |
| Director/PDMR Shareholding | 19 Nov 2024 |
| GSK announces overall survival results for Blenrep | 14 Nov 2024 |
| Block listing Interim Review | 13 Nov 2024 |
| Director/PDMR Shareholding | 12 Nov 2024 |
| GSK publishes provisional 2025 dividend dates | 11 Nov 2024 |
| Total Voting Rights | 1 Nov 2024 |
| 3rd Quarter Results | 30 Oct 2024 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 30 Oct 2024 |
| New positive Arexvy data in younger adults at risk | 24 Oct 2024 |
| Director/PDMR Shareholding | 17 Oct 2024 |
| FDA accepts new drug application for gepotidacin | 16 Oct 2024 |